NCRI 2021 | FOCUS4-C: Adavosertib in metastatic colorectal cancer

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, discusses the results of the FOCUS4-C trial (EudraCT Number: 2012-005111-12), which assessed the WEE1 inhibitor adavosertib in patients with newly diagnosed TP53- and RAS-mutant metastatic colorectal cancer. Patients initially received 16 weeks of chemotherapy and then received adavosertib or active monitoring. The primary endpoint of progression-free survival (PFS) was met in the adavosertib arm, and adavosertib particularly benefited patients with left-sided primary tumors or KRAS exon 12/13 mutations. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.